Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02431936|
Recruitment Status : Completed
First Posted : May 1, 2015
Last Update Posted : June 20, 2019
|Condition or disease||Intervention/treatment||Phase|
|Hypertension Stress, Psychological Blood Pressure||Drug: Prazosin Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress in a Randomized Double Blind Placebo Controlled Design|
|Study Start Date :||April 2015|
|Actual Primary Completion Date :||April 16, 2019|
|Actual Study Completion Date :||April 16, 2019|
Prescription for 1mg oral Prazosin twice per day will be administered for 71/2 days.
Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
Other Name: minipress
Placebo Comparator: Placebo
Prescription for placebo identical to Prazosin dosage will be administered for twice daily for 71/2 days.
Sugar pill made to look identical to Prazosin intervention.
Other Name: sugar pill
- Urinary sodium excretion rate [ Time Frame: 2 hours ]Primary variable of interest is the difference in stress induced changes in sodium excretion between placebo and treatment conditions in African-Americans who retain sodium during stress.
- Hemodynamics: change in systolic blood pressure [ Time Frame: 2 hours ]Measures of change in systolic blood pressure compared to changes in sodium excretion in treatment versus placebo in African-Americans who retain sodium during stress.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02431936
|United States, Georgia|
|Augusta, Georgia, United States, 30912|
|Study Director:||Gregory A Harshfield, PhD||Augusta University|